Tag: biotechnology
AbCellera Biologics Stock Analysis: Buy or Sell? Valuation & Cash Burn
AbCellera Biologics Inc. (ABCL) is rated STRONG SELL as valuation still assumes a much faster clinical and commercial ramp than current results support. Despite a large cash balance, ongoing cash burn and rich revenue multiples leave little margin of safety.
Vertex Pharmaceuticals Stock Analysis: Buy or Sell? Valuation, Free Cash Flow & Margin
Vertex Pharmaceuticals (VRTX) is rated HOLD as rich valuation leaves little margin for disappointment, even with strong free cash flow and a solid balance sheet. CF concentration remains the key risk, while new launches must keep scaling to justify the current multiple.
Viking Therapeutics Stock Analysis: Buy or Sell? Cash Burn & Valuation
Viking Therapeutics (VKTX) is rated STRONG SELL because heavy cash burn is consuming a large cash balance while the stock still trades at a rich valuation. Phase 3 obesity progress remains the key swing factor, but the current risk/reward looks unfavorable.
CRISPR Therapeutics Stock Analysis: Buy or Sell? Valuation, Cash Burn & Growth Outlook
CRISPR Therapeutics AG (CRSP) is rated STRONG SELL as its valuation already prices in a much faster commercial ramp than current revenue and cash generation support. With heavy cash burn and negative operating cash flow, the stock leaves little margin for error despite a strong balance sheet.
Amgen Stock Analysis: Buy or Sell? Valuation, Cash Flow & Debt
Amgen (AMGN) is rated Hold because strong cash generation supports the business, but the valuation already reflects much of that quality. The key concern is elevated debt and policy-driven pricing pressure, which limit upside despite a 35.6% operating margin and solid free cash flow.
Ironwood Pharmaceuticals Stock Analysis: Buy or Sell? FCF, Valuation, Pipeline
Ironwood Pharmaceuticals (IRWD) is rated Hold as LINZESS continues to generate real free cash flow, but apraglutide has faced delays and the stock already reflects much of the progress. The main debate is whether cash generation can offset LINZESS concentration and the 2027 Medicare price reset.
Cue Biopharma Stock Analysis: Buy or Sell? Cash Burn, Dilution & Valuation
Cue Biopharma (CUE) is rated Sell as cash burn and dilution risk outweigh the promise of its Immuno-STAT pipeline. A 5.1x EV/revenue valuation and just $27.1 million of year-end cash leave little room for delay before clinical proof arrives.
GeneDx Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margins
GeneDx Holdings Corp. (WGS) is rated Sell as the market prices in a clean earnings recovery that cash flow and margin trends do not yet support. Revenue growth is improving, but positive free cash flow remains elusive and reimbursement pressure could delay a rerating.